Corrigendum


- The second, third, and fourth sentences of the abstract, as well as the last paragraph of the abstract, except for the second sentence (pp. 211)
- ‘Vaccines against nicotine’ (pp. 217)
- The first two paragraphs in ‘Vaccines against nicotine under evaluation in clinical trials’ (pp. 218) with the exception of the last sentence in the second paragraph
- ‘Cytos AG, Schlieren Switzerland’ (pp. 218)
- ‘Phase II study of vaccine NIB002’ (pp. 218)
- ‘Celtic pharma holdings LP’ (pp. 219) with the exception of the third-to-last and fourth-to-last sentences
- ‘Nabi Inc’ (pp. 220) with the exception of the last two sentences
- ‘Chilka Ltd and other competitors developing nicotine vaccines’ (pp. 220)
- ‘Further developments to expect’ (pp. 220)